SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: marc ultra who wrote (2651)9/2/1999 11:37:00 PM
From: tom jones  Read Replies (2) | Respond to of 4676
 
To all: Boehringer Ingelheim may have dropped out so they will not have to pay the milestone payments for 2302. They will be receiving royalties for 2302 sales. This is not a blockbuster drug, there are only 800,000 people with Crohn's disease world wide and most will not need 2302. This may have just been a good business decision by Boehringer Ingelheim and had nothing to do with the 2302 trials.
Tom



To: marc ultra who wrote (2651)9/4/1999 8:41:00 PM
From: Scott H. Davis  Read Replies (1) | Respond to of 4676
 
Thanks 4 the tip. Good call, lots of positive things. Will try 2 post more later (got soem end of month and project reporting due end of tomorrow) Scott


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News